Drug intelligence / Profile preview

Mynflu002

Development stage: Preclinical
Lead developer: Mynvax
Modality: Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Mynflu002 is a preclinical-stage recombinant protein subunit vaccine being developed by Mynvax for the prevention of influenza. The vaccine is designed to be multivalent and adjuvanted, targeting the hemagglutinin (HA) protein and other conserved antigens specifically from H1 and H3 influenza strains. By focusing on conserved regions of the influenza virus, Mynflu002 aims to provide broader and more durable protection compared to traditional seasonal flu vaccines, potentially reducing the need for frequent strain updates.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on Mynflu002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mynflu002.

Explore the full profile